BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lixisenatide: Phase III data

Top-line data from the open-label, international Phase III GetGoal-X trial in 639 Type II diabetics inadequately controlled with metformin showed that once-daily lixisenatide as an add-on to metformin met the primary endpoint of non-inferiority to twice-daily Byetta exenatide plus metformin in reducing HbA1c from baseline to week 24. Additionally, a significantly smaller proportion of patients...

Read the full 261 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >